Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 5/20 | 0.39 |
| ▸ | BCL2L2 | Q92843 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596864 | 1.00 | KMT2A (0.44) | KMT2ASMN1; SMN2BCL2BCL2L2POLB | |
| SCHEMBL4596857 | 1.00 | KMT2A (0.44) | KMT2ASMN1; SMN2BCL2BCL2L2POLB | |
| SCHEMBL4597654 | 0.82 | SMN1; SMN2 (0.43) | KMT2ASMN1; SMN2BCL2BCL2L2POLB | |
| SCHEMBL6206249 | 0.82 | SMN1; SMN2 (0.43) | KMT2ASMN1; SMN2BCL2BCL2L2POLB | |
| SCHEMBL4595768 | 0.81 | L3MBTL1 (0.44) | KMT2ASMN1; SMN2POLBMCL1L3MBTL1 | |
| SCHEMBL4595759 | 0.81 | L3MBTL1 (0.44) | KMT2ASMN1; SMN2POLBMCL1L3MBTL1 | |
| SCHEMBL4597380 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2BCL2BCL2L2MCL1GAA | |
| SCHEMBL4597413 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2BCL2BCL2L2MCL1GAA | |
| SCHEMBL4597376 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2BCL2BCL2L2MCL1GAA | |
| SCHEMBL15194881 | 0.78 | KMT2A (0.46) | KMT2APOLBL3MBTL1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414444-B1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-09 | — | — | EP | disclosed |
| EP-1506177-B1 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF 2-SUBSTITUTED 2-(2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACID DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-6962937-B2 | Imidazolidine derivatives, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| US-6908752-B2 | Process for the preparation of the enant iomeric forms of 2-substituted 2- (2, 5-dioxoimidazolidin-1yl) -acetic acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-21 | — | — | US | disclosed |
| EP-1506177-A2 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF 2-SUBSTITUTED 2-(2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACID DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2005-02-16 | — | — | EP | disclosed |
| EP-1414444-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2004-05-06 | — | — | EP | disclosed |
| US-6667334-B1 | Inhibitors of adhesion and migration of leukocytes and/or antagonists of adhesion receptor VLA-4 belonging to integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-23 | — | — | US | disclosed |
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | US | disclosed |
| US-20030054507-A1 | Process for the preparation of the enant iomeric forms of 2-substituted 2- (2, 5-dioxoimidazolidin-1-yl) -acetic acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003011288-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003008386-A2 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF 2-SUBSTITUTED 2-(2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACID DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | VCAM1, ITGA1, ITGA4 | KMT2A 1692/4885SMN1; SMN2 3909/4885BCL2 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.